Objectives: Prescription drug abuse is a major public health problem in the United States, with the rate of opioid-related deaths nearly quadrupling between 2000 and 2014. Extended-release oral oxymorphone hydrochloride (Opana ER) is a long-acting opioid prescribed for chronic pain; however, it also has the potential to be abused via intravenous injection. This retrospective review sought to analyze specific complications and sequelae requiring intensive care unit resources for patients intravenously abusing extended-release oral oxymorphone.
U S President Richard M. Nixon declared an official "war on drugs" in June 1971, citing concerns for public safety. 1 Illicit drugs such as cocaine, heroin, marijuana, and methamphetamine were specifically targeted by the policy; however, an inadvertent consequence to the "war on drugs" was an increased prevalence of prescription drug abuse, specifically opiates, during the last 4 decades. The rate of death from prescription opioid overdose has nearly quadrupled from 2000 to 2014, accounting for nearly 5.9 deaths/100,000 persons. 2 Abuse patterns range from excess consumption of oral opioid medication to illicit methods, including insufflation (snorting) and injecting. Lansky et al estimated that individuals who inject drugs are approximately 2.6% of the population, or 6.6 million injection drug users, older than 13 years in the United States. 3 The Centers for Disease Control and Prevention has recognized an opioid abuse epidemic throughout the United States, with overdose deaths from prescription pain medications surpassing deaths from heroin and cocaine combined. 4 Specifically, in North Carolina prescription medications have been identified as the leading cause of overdose death, with an increase of >300% since 1999. 5 In our experience, extended-release oral oxymorphone, particularly Opana ER (Endo Pharmaceuticals, Malvern, PA), has been implicated frequently as a preferred opioid for intravenous drug abuse among patients admitted to our tertiary care medical facility for associated complications related to abuse.
Opana ER is a long-acting oral formulation of the opioid oxymorphone, primarily intended for treatment of moderate to severe chronic pain. 6 Although oxymorphone can provide substantial basal analgesia, the potential for abuse is high. To prevent continued abuse Opana ER was reformulated in 2011 to be "crush resistant"; however, in our patient population, misuse of this opioid remains common. In academic tertiary care medical centers, clinicians frequently provide care for patients who are illicitly abusing intravenous drugs. In our patient population extended-release oral oxymorphone has been recognized empirically as both a common and preferred drug of intravenous abuse and identified by the brand name Opana ER. In addition, intravenous abuse of extended-release oral oxymorphone has been recognized as a direct and rapid cause of human immunodeficiency virus in a small community in Indiana. 7 We have observed the severe clinical deterioration associated with intravenous abuse of extended-release oral oxymorphone through numerous clinical encounters at our academic medical center, often in the critical care setting. In the present case series, we retrospectively identified 165 patients who intravenously injected extended-release oral oxymorphone and examined the use of critical care resources and myriad associated adverse outcomes.
Methods
We reviewed the medical records of patients identified for drug abuse between January 2012 and December 2015. Our institutional review board granted approval to access medical records and collect patient data. At our academic medical center, there were approximately 92,000 total admissions during the timeframe of this investigation. Retrospective chart review and analysis were performed on these admissions to identify documentation of "drug abuse" in the electronic medical record by a physician or provider, resulting in the identification of 2350 patients. The 2350 patient charts were queried for use of "extended-release oxymorphone" or "Opana." Patients then were subdivided to identify individuals who were intravenously injecting the medication. Demographic and clinical variables were collected and analyzed for those patients intravenously injecting extended-release oral oxymorphone who required admission into a medical, surgical, or trauma intensive care unit (ICU). Secondary outcomes included the need for endotracheal intubation with mechanical ventilation, use of vasopressor agents for hemodynamic instability, infectious complications, and acute kidney injury (AKI).
Results
We identified 302 patients with documented extended-release oral oxymorphone or Opana ER use; 165 of these patients had documented intravenous abuse of extended-release oral oxymorphone, including 53 patients who required ICU admission. The following results are an analysis of those identified specifically requiring admission to an ICU.
The average age was 34.4 years (range 21-62 years), with a slight predominance of women (52.8%), as noted in the Table. The average length of stay in the ICU was 5.94 days and ranged from 1 to 26 days. The Figure briefly summarizes the patient characteristics and numerous clinical complications that resulted from injection of extended-release oral oxymorphone in patients admitted to an ICU.
The most commonly encountered complication identified was AKI, with 48 patients (90.6%) diagnosed. Among those with AKI, 13 patients (24.5%) required initiation of continuous renal replacement therapy in the ICU and 2 patients (3.8%) required intermittent hemodialysis. The average length of time that a patient received continuous renal replacement therapy was 1.60 days. Spontaneous renal recovery with supportive care occurred in four patients, whereas nine patients developed end-stage renal disease requiring permanent intermittent hemodialysis. Furthermore, the 48 patients diagnosed as having AKI were stratified into three categories: septic shock (characterized as positive blood cultures and need for vasopressor support given persistent hypotension), shock (characterized as negative blood cultures and need for vasopressor support given persistent hypotension), and bacteremia (characterized as positive blood cultures without persistent hypotension). There were 20 (41.7%), 2 (4.2%), and 16 (33.3%) patients, respectively, in these subcategories.
We identified 28 patients (52.8%) who required endotracheal intubation with mechanical ventilation; intubation was most commonly the result of acute hypoxic respiratory failure or failure of a patient to adequately protect his or her airway. The average length of time for patients requiring mechanical ventilation was 3.0 days. In our case series one patient required tracheostomy tube placement for chronic hypoxic respiratory failure. Among the patients with respiratory failure, 10 patients (35.7%) were classified as having both hypoxic and hypercarbic respiratory failure, whereas 18 (64.3%) were classified as having hypoxic respiratory failure. No patient required endotracheal intubation with mechanical ventilation for purely hypercarbic respiratory failure.
Infection also was identified as a common and serious complication from intravenous abuse of oral oxymorphone; bacteremia, soft tissue infections, and endocarditis were the most commonly documented sites of infection. There were 36 patients (67.9%) with at least one noncontaminant positive blood culture during hospitalization. Methicillin-resistant Staphylococcus aureus was isolated in 16 of the positive blood cultures, accounting for 44.4% of the bacteremia in the ICU. There were 15 positive blood cultures for methicillin-susceptible Staphylococcus aureus, accounting for 41.7% of cases. Other blood culture isolates included streptococcus (alpha-and beta-hemolytic), Pseudomonas aeruginosa, Klebsiella pneumoniae, and coagulase-negative staphylococci. Among the 36 patients with positive blood cultures, 20 (55.6%) developed septic shock that required vasopressor support.
Thirty-two patients (60.4%) developed or formed an abscess or cellulitis believed to be secondary to intravenous oxymorphone abuse. Superficial skin and soft tissue infections related to the injection site were the most frequently encountered; several patients developed deep abscesses in the thoracic and abdominal cavities, which required surgical debridement. There were also five patients (9.4%) who presented with or developed osteomyelitis; cervical involvement was seen in three of these cases. Furthermore, the 32 patients diagnosed as having an abscess or cellulitis were stratified into three categories: septic shock, shock, and bacteremia. There were 16 (50.0%), 1 (3.1%), and 10 (31.3%) patients, respectively, in these subcategories. Acute bacterial endocarditis was diagnosed in 30 patients (56.6%) in the ICU by visualization of vegetations on transthoracic or transesophageal echocardiogram in combination with positive blood culture results. Despite aggressive supportive care in the ICU, six deaths resulted secondary to the development of profound multisystem organ failure refractory to aggressive resuscitative treatment therapies. Several additional deaths in the patient cohort occurred after discharge from the ICU.
Discussion
Prescription opioid abuse continues to be a serious public health concern in the United States and affects a wide array of patients.
Patients intravenously abusing extended-release oral oxymorphone, specifically Opana ER, are frequently cared for at our academic medical center because of sequelae and complications associated with injection. We suspect that we have a disproportionately high level of intravenous abuse of extended-release oral oxymorphone compared with other regions of the United States. In 2012, the Centers for Disease Control and Prevention issued a report implicating the intravenous abuse of extendedrelease oral oxymorphone causing a pathologic disease state similar to thrombotic thrombocytopenic purpura (TTP). 8 Shortly after the report was released, a case series recommended aggressive supportive care rather than therapeutic plasma exchange for the treatment of the underlying thrombotic microangiopathy resulting from the intravenous abuse of extended-release oral oxymorphone because no severe deficiency of ADAMTS13 or autoantibody to ADAMTS13 was identified. This indicated a different underlying etiology of intravenously abused extended-release oral oxymorphone-induced thrombotic microangiopathy compared with TTP, despite similarities in clinical presentation.
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ADAMTS13 is a Von Willebrand-cleaving plasma enzyme that becomes deficient in TTP secondary to an autoantibody; treatment of TTP is directed toward the replacement of deficient ADAMTS13 with therapeutic plasma exchange and removal and suppression of the ADAMTS13 autoantibody. 10 Our case series demonstrates a pattern of high utilization of critical care resources resulting from the development of numerous life-threatening complications. There remains limited recognition of this crisis, likely because intravenous abuse of extended-release oral oxymorphone is isolated to particular regions in the United States and not yet widespread. For these reasons we suspect it is infrequently considered as the underlying risk factor responsible for a presenting illness. As such, danger lies in this general unawareness if the preferred abuse of oxymorphone continues to spread.
AKI was based on the 2012 definition from Acute Kidney Injury Work Group: Kidney Disease Improving Global Outcomes 11 and was present in an overwhelming 90.6% of patients admitted to an ICU. Almost 25% of those with AKI required renal replacement therapy and 2 patients (3.8%) required initiation of intermittent hemodialysis; however, the exact pathophysiology of the AKI remains to be determined. There are likely multifactorial components, including but not limited to thrombotic microangiopathy, hypotension, and iatrogenic-induced factors (eg, antibiotics, vasopressors). Hunt et al have explored this mechanism of kidney injury by investigating the effects of intravenous extended-release oral oxymorphone injection into model guinea pigs. 12 Their work suggests a different mechanism of nephrotoxicity compared with TTP and secondary to multifactorial etiologies, including dose-dependent glomerular and oxidative tissue damage caused by extracellular hemoglobin, heme, and iron. Renal hypoxia was observed with increased levels of hypoxia-inducible factor 1.
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In our cohort, most patients admitted to the ICU secondary to injection of oral oxymorphone developed complications from underlying infections. Specifically, 67.9% of patients were diagnosed as having bacteremia that we suspect was related to improper skin cleansing preinjection or the possible use of contaminated needles. We also identified acute bacterial endocarditis in 56.6% of the cohort; however, we suspect the incidence in our cohort would be even higher had Duke Criteria been able to be calculated for each patient. Unfortunately, this was not possible given the limitations of our retrospective study, but it remains a prospective interest.
Acute bacterial endocarditis is a life-threatening emergency and prompt recognition and treatment is crucial. According to an analysis by Wallace et al, overall mortality from infective endocarditis is approximately 18% at the time of discharge and 27% at 6 months for a 200-patient sample size, including 19 patients with intravenous drug abuse. 13 Given the high rates of infectious complications, including endocarditis in patients intravenously abusing extended-release oral oxymorphone, we recommend early, aggressive, empiric broad-spectrum antibiotics as treatment for those patients admitted to the ICU in lieu of conservative monitoring while the remainder of the infectious workup is conducted.
Conclusions
To our knowledge, this is the first and largest case series to analyze specific complications requiring ICU resources in patients intravenously abusing extended-release oral oxymorphone. Our analysis demonstrates the significant disease burden because nearly one-third of the patients had critical illness resulting in admission into an ICU for aggressive medical care.
Physicians and providers who initially evaluate and triage patients, such as those practicing in primary care offices, urgent care centers, and emergency departments, should be highly vigilant for the potential of clinical decompensation, be suspicious for infectious sequelae, and assess the need for a higher level of care secondary to the intravenous abuse of extended-release oral oxymorphone or Opana ER. It also is important to note that in our experience, patients reported use or abuse of Opana ER, but did not reliably report when asked about oxymorphone use or abuse.
In our experience and review of the literature, the intravenous abuse of extended-release oral oxymorphone appears to be increasing and disproportionately affecting the southeastern United States compared with other regions or globally; however, the potential for outspread certainly exists. Expansion of abuse to previously unrecognized locations will require astute awareness to promptly provide appropriate levels of medical care. The numerous sequelae associated with the intravenous abuse of extended-release oral oxymorphone have proven serious and contribute to the identified state-specific increase in opioid-related deaths. Furthermore, the increases in morbidity and the expenditure on medical care affect local, state, and national governments as a whole. The response to this crisis is vital, with the dissemination of information being paramount. Our experience can serve as a catalyst for early consideration and recognition of the intravenous abuse of extended-release oral oxymorphone related to critical illness sequelae.
